The Hyperliquid Policy Center has requested the SEC to clarify how its proposed crypto fundraising rules will treat airdrops, secondary token trading, and projects qualifying for a safe harbor exemption. The center supports the SEC's Regulation Crypto Assets, which allows startups to raise funds under certain limits with disclosure and antifraud rules. Key clarifications sought include defining airdrops that don't create investment contracts, the role of unregistered intermediaries in token trades, and protections for tokens no longer tied to investment contracts. These clarifications aim to help crypto projects navigate fundraising and trading within clear regulatory boundaries.
The Hyperliquid Policy Center's request for SEC clarity on crypto fundraising rules provides context for market observers. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 19, 2026 22:31 WIB: 41 of 50 major cryptocurrencies rose today. SNX was priced at Rp3.868 with a 3.17% increase, XRP at Rp23.517 rose 3.09%, and LINK at Rp216.624 gained 3.03%.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
